Dr Greg Mattingly shares his view on major challenges in the management of Major Depressive Disorder and limitations of medications currently used.

Dr Andrew Cutler and Dr Greg Mattingly discuss newer mechanisms of action to treat patients with Major Depressive Disorder, in particular those with glutamatergic agents.

Dr Greg Mattingly explains the mechanism of action of dextromethorphan-bupropion, a new agent to treat Major Depressive Disorder.

Dr Greg Mattingly reviews the results of GEMINI and ASCEND trials, which led to approval of dextromethorphan-bupropion.

The expert psychiatrists share their clinical experience with dextromethorphan-bupropion.

Dr Andrew Cutler and Dr Greg Mattingly talk about patient profiles they consider for treatment with dextromethorphan-bupropion.

The expert psychiatrists discuss when to evaluate treatment efficacy and the impact of patients’ quality of life and function in such evaluations.

Dr Andrew Cutler and Dr Greg Mattingly review current understanding of anhedonia. They discuss how clinicians can better evaluate it by effectively and candidly communicating with patients about anhedonia.

Dr Andrew Cutler and Dr Greg Mattingly comment about emerging treatments to treat anhedonia and highlight lifestyle modifications that support the wellbeing of patients with Major Depressive Disorder.